Effectiveness of the concomitant use of Bivalirudin and drug-eluting stents (from the Prospective, Multicenter BivAlirudin and Drug-Eluting STents [ADEST] Study)

American Journal of Cardiology

Volumn 96, Issue 5, 2005, Pages 659-663

  Dangas, George ^a   Lasic, Zoran ^b   Mehran, Roxana ^a   Cox, David ^c   Ghali, Magdi G H ^d   Henry, Timothy D ^e   Teirstein, Paul S ^f   Stella, Joseph F ^g   Browne Jr , Kevin F ^h   Lewis, Stephen Alan ⁱ   Knopf, William ^j   Leon, Martin B ^a   Moses, Jeffrey W ^a   Stone, Gregg W ^a  

^a NewYork Presbyterian Hospital   (United States)

^b LENOX HILL HOSPITAL   (United States)

^c Mid Carolina Cardiology   (United States)

^d IOWA HEART CENTER   (United States)

^e MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^f SCRIPPS CLINIC   (United States)

^g Heart Care Research Foundation   (United States)

^h Watson Clinic   (United States)

ⁱ CHARLESTON AREA MEDICAL CENTER   (United States)

^j Atlanta Cardiovasc Res Institute   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; CREATINE KINASE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; RAPAMYCIN; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BLEEDING DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; HEART DISEASE; HEART INFARCTION; HEART INJURY; HEART MUSCLE REVASCULARIZATION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; Q WAVE; RISK FACTOR; THROMBOSIS; TIME SERIES ANALYSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNITED STATES;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY DISEASE; CORONARY RESTENOSIS; FOLLOW-UP STUDIES; HIRUDINS; HOSPITAL MORTALITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RISK FACTORS; SAFETY; SIROLIMUS; STENTS; TREATMENT OUTCOME; UNITED STATES;

EID: 23944481818     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.04.039     Document Type: Article

References (11)

1. D.E. Cutlip, D.S. Baim, K.K. Ho, J.J. Popma, A.J. Lansky, D.J. Cohen, J.P. Carrozza Jr, M.S. Chauhan, O. Rodriguez, R.E. Kuntz Stent thrombosis in the modern era a pooled analysis of multicenter coronary stent clinical trials Circulation 103 2001 1967 1971
2. M.C. Morice, P.W. Serruys, J.E. Sousa, J. Fajadet, E. Ban Hayashi, M. Perin, A. Colombo, G. Schuler, P. Barragan, G. Guagliumi, F. Molnar, R. Falotico RAVEL Study Group Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization N Engl J Med 346 2002 1773 1780
3. J.W. Moses, M.B. Leon, J.J. Popma, P.J. Fitzgerald, D.R. Holmes, C. O'Shaughnessy, R.P. Caputo, D.J. Kereiakes, D.O. Williams, P.S. Teirstein, J.L. Jaeger, R.E. Kuntz SIRIUS Investigators Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
4. J. Schofer, M. Schluter, A.H. Gershlick, W. Wijns, E. Garcia, E. Schampaert, G. Breithardt E-SIRIUS Investigators Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries double-blind, randomised controlled trial (E-SIRIUS) Lancet 362 2003 1093 1099
5. http://www.fda.gov/cdrh/safety/cypher.html. Accessed July 9, 2004.
6. http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01267.html. Accessed July 9, 2004.
7. A.M. Lincoff, J.A. Bittl, N.S. Kleiman, I.J. Sarembock, J.D. Jackman, S. Mehta, M.A. Tannenbaum, A.L. Niederman, W.B. Bachinsky, J. Tift-Mann III REPLACE-1 Investigators Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial) Am J Cardiol 93 2004 1092 1096
8. A.M. Lincoff, J.A. Bittl, R.A. Harrington, F. Feit, N.S. Kleiman, M.D. Jackman, I.J. Sarembock, D.J. Cohen, D. Spriggs, R. Ebrahimi REPLACE-2 Investigators Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. REPLACE-2 randomized trial JAMA 289 2003 853 863
9. P.A. Lemos, A. Hoye, D. Goedhart, C.A. Arampatzis, F. Saia, W.J. van der Giessen, E. McFadden, G. Sianos, P.C. Smits, S.H. Hofma Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study Circulation 109 2004 1366 1370
10. E. Regar, P.A. Lemos, F. Saia, M. Degertekin, K. Tanabe, C.H. Lee, C.A. Arampatzis, A. Hoye, G. Sianos, P. de Feyter Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients Am J Cardiol 93 2004 1271 1275
11. A. Jeremias, B. Sylvia, J. Bridges, A.J. Kirtane, B. Bigelow, D.S. Pinto, K.K. Ho, D.J. Cohen, L.A. Garcia, D.E. Cutlip, J.P. Carrozza Jr Stent thrombosis after successful sirolimus-eluting stent implantation Circulation 198 2004 1930 1932